Doravirine Concentrations and Antiviral Activity in Genital Fluids in HIV-1 Infected Individuals

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia30 enrolled

Overview

This study aims to evaluate the ability of Doravirine to penetrate the genital tract and suppress viral replication and provide evidence for the use of Doravirine as part of treatment strategies as prevention.

Objectives: * To determine Doravirine concentrations in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals receiving antiretroviral therapy (ATR) with Doravirine plus Descovy®. * To evaluate HIV-1 viral load in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals receiving ART with Doravirine plus Descovy®. Study Phase: Phase II Study Design: Open label, single arm, single center, prospective study. Study Disease: HIV-1 infection Study Endpoints: * Concentration of Doravirine in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals, respectively, 8 weeks after switching to Doravirine plus Descovy®. * HIV-1 RNA in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals, respectively, 8 weeks after switching to Doravirine plus Descovy®. Target Population: Male and female adult HIV-1 infected patients receiving standard ART with tenofovir alafenamide/emtricitabine (TAF/FTC), tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine , plus an non-nucleoside reverse transcriptase inhibitor, a boosted protease inhibitor or an integrase inhibitor during at least 3 months, with plasma HIV-1 RNA suppression (\<40 copies/mL) during at least 6 months. Number of Subjects Planned: 15 male and 15 female individuals. Study duration: 16 weeks

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

HIV-1-infection

Interventions

DoravirineDRUG

Doravirine 100 mg tablet

DescovyDRUG

Tenofovir alafenamide 25 mg / emtricitabine 200 mg tablet

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Asymptomatic, HIV-1 infected individuals ≥ 18 years of age. 2. Be on a stable ART consisting of TAF/FTC, tenofovir disoproxil fumarate/emtricitabine or abacavir/lamivudine, plus an non-nucleoside reverse transcriptase inhibitor, a boosted protease inhibitor or an integrase inhibitor, continuously for at least 3 consecutive months preceding the screening visit. 3. Plasma HIV-1 RNA \<40 copies/mL for at least 6 months at the Screening visit. 4. Signed and dated written informed consent prior to inclusion. 5. Female Subjects of Childbearing Potential must agree to utilize a highly effective method of contraception during heterosexual intercourse from the screening visit throughout the duration of the study. Exclusion Criteria: 1. Severe hepatic impairment (Child-Pugh Class C) 2. Ongoing malignancy 3. Active opportunistic infection 4. Resistance to any of the antiretroviral (ARV) included in the study or history of virologic failure with risk of resistance selection to any of the study drugs. 5. Any verified Grade 4 laboratory abnormality 6. ALT or AST ≥ 3xULN and/or bilirubin ≥ 1.5xULN 7. Severe renal impairment (Estimated creatinine filtration rate \<50mL/min). 8. Females who are pregnant (as confirmed by positive serum pregnancy test) or breastfeeding.

Locations (1)

Hospital Universitari de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Outcomes

Primary Outcomes

Concentration of Doravirine in Seminal Plasma Fluid

Concentration of Doravirine in seminal plasma fluid in HIV-1 infected male individuals

Time frame: 8 weeks after switching (from baseline visit) to Doravirine plus TAF/FTC

Concentration of Doravirine in Cervicovaginal Fluid

Concentration of Doravirine in cervicovaginal fluid in HIV-1 infected female individuals

Time frame: 8 weeks after switching to Doravirine plus TAF/FTC

Number of Participants With HIV-1 RNA Seminal Plasma <40 Copies/mL

Number of participants with HIV-1 RNA seminal plasma \<40 Copies / mL of HIV measured by real-Time Reverse Transcriptase Polymerase Chain Reaction Amplification

Time frame: 8 weeks after switching (from baseline visit) to Doravirine plus TAF/FTC

Quantification of Participants With HIV-1 RNA <40 Copies / mL in Cervicovaginal Fluid

Number of participants with HIV-1 RNA cervicovaginal fluid\<40 Copies / mL of HIV measured by real-Time Reverse Transcriptase Polymerase Chain Reaction Amplification

Time frame: 8 weeks after switching (from baseline visit) to Doravirine plus TAF/FTC

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.